The main objective is to investigate if percutaneous needle aponeurotomy is non-inferior to open surgery using aponeurectomy in treatment of flexion contracture due to Dupuytren's disease. Our hypothesis is that percutaneous needle aponeurotomy has suitable efficacy and safety profile for large application in the treatment of Dupuytren's disease and that it is consequently able to drastically reduce the need of open surgery in this indication.
Scientific justification: Dupuytren's disease is a world-wide musculoskeletal disorder. It consists in fibrosis of the palmar aponeurosis that can induce disabling flexion contracture of the metacarpophalageal or proximal interphalangeal joints. Treatment modalities of flexion contracture include open surgery, percutaneous needle aponeurotomy and collagenase. Collagenase is not available in France. Aponeurectomy, that is also called fasciectomy, is the main open surgical technique, and open surgery is the most frequently used treatment in Dupuytren's disease. Percutaneous needle aponeurotomy is recommended as a nonsurgical treatment for Dupuytren's disease. It is a minimally invasive procedure. Its most largely accepted indication is Dupuytren's disease with metacarpophalageal joint involvement. However, percutaneous needle aponeurotomy has been successful for metacarpophalageal or proximal interphalangeal joint involvement, in nonadvanced and in advanced Dupuytren's disease. A model analysis recently demonstrated that replacing open surgery with percutaneous needle aponeurotomy could save more than 50% of the total hospitalization costs for the disease. Percutaneous needle aponeurotomy therefore appears as a unique minimally invasive approach for Dupuytren's disease. It could become a valuable alternative to open surgery. The hypothesis is that percutaneous needle aponeurotomy has suitable efficacy and safety profile for large application in the treatment of Dupuytren's disease and that it is consequently able to drastically reduce the need of open surgery in this indication. Practical procedure: Patients addressed to the consultation of the hand surgery centers for Dupuytren's disease will be prospectively selected, included, randomized, treated using percutaneous needle aponeurotomy or open surgery within six weeks after randomization, and followed at 1 week, 1, 3,12, 24 and 36 months after treatment. Assessment of efficacy will be blinded. Assessment of complications will be done by an unblinded assessor.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
120
It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
Centre d'Imagerie Médicale Bachaumont Paris Centre
Paris, France
ACTIVE_NOT_RECRUITINGHopital LARIBOISIERE - Radiologie
Paris, France
ACTIVE_NOT_RECRUITINGHopital LARIBOISIERE - Rhumatologie
Paris, France
RECRUITINGMetacarpophalangeal joint contracture during passive extension
Expressed in degrees, using low energy computed tomography for blinded assessment (computed tomography imaging will be analysed by a blinded assessor not involved in the treatment). Baseline will be Metacarpophalangeal joint contracture during passive extension the day of the treatment, before any treatment
Time frame: at 3 months after treatment
Metacarpophalangeal joint contractures during passive and active extension
Expressed in degrees using clinical goniometry, and patient wearing white opac gloves to ensure blinded assessment.
Time frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
Main metacarpophalangeal joint contracture during passive extension,
Expressed in degrees, using low energy computed tomography, for blinded assessment (computed tomography imaging will be analysed by a blinded assessor not involved in the treatment).
Time frame: at 36 months after treament
The clinical success
The clinical success is defined as the reduction of flexum to within 0 to 5° during passive extension, using clinical goniometry, for the main metacarpophalangeal joint); Patient will wear white opac gloves to ensure blinded assessment.
Time frame: at 3 months after treament
The recurrence
The recurrence is defined as the flexum progression of 20°, during passive extension, using clinical goniometry, after clinical success. Patient will wear white opac gloves to ensure blinded assessment.
Time frame: at 12, 24 and 36 months after treament
The interphalangeal joint contractures during passive and active extension
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
JOUVENET - Orthopédie, chirurgie de la main et du membre supérieur
Paris, France
RECRUITINGExpressed in degrees, using clinical goniometry. Patient will wear white opac gloves to ensure blinded assessment.
Time frame: at 1 week, 1, 3,12, 24 and 36 months after treatment
The 70% improvement from baseline of the flexion contracture
The flexion contracture of each treated joint, during passive extension will be assessed by a blinded assessor (Patient will wear white opac gloves). - Flexion contracture in degrees using goniometry reported as follows: ray Number; metacarpophalangeal angle; interphalangeal angle
Time frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
The active range of motion of metacarpophalangeal and proximal interphalangeal treated joints
The active range of motion of metacarpophalangeal and proximal interphalangeal treated joints will be assessed by a blinded assessor (Patient will wear white opac gloves).
Time frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
The functional limitation using Quick DASH questionnaire
The patient will fill out the auto-questionnaire. The blinded assessor will calculate the score (0 to 100, with highest value indicating highest disability).
Time frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
The URAM scale
The patient will fill out the auto-questionnaire. The blinded assessor will calculate the score (0 to 45, with highest value indicating highest disability).
Time frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
The patient satisfaction on a 0-100 mm visual analog scale
The assessor will ask the patient the following question: "How would you rate satisfaction about the treatment you underwent in the study?" Patients will be asked to mark the level of their satisfaction on a l00-mm, nonhatched VAS scale marked at one end as "not satisfied" and at the other as "completely satisfied''
Time frame: at 1 week, 1, 3, 12, 24 and 36 months after treatment
The number of secondary and repeated treatments
The number of secondary or repeated open surgeries and percutaneous needle aponeurotomy will be recorded by the unblinded assessor.
Time frame: at 12, 24 and 36 months after treatment
Complications and adverse events for primary treatment
The number and the types of complications and adverse events for primary open surgery and first line percutaneous needle aponeurotomy will be collected by an unblinded assessor.
Time frame: at the treatment time, and at 1 week, 1, 3, 12, 24 and 36 months;
Complications and adverse events for secondary treatment
The number and the types of complications and adverse events for secondary open surgery and percutaneous needle aponeurotomy will be collected by an unblinded assessor.
Time frame: at the treatment time, at 12, 24 and 36 months;
The post-interventional pain and needs
The post-interventional pain and needs of nursing, splinting, medication, physiotherapy,sick leave, time return to regular activities using a patient diary. These datas will be collected by the unblinded assessor.
Time frame: at 1 week, 1, 3, 12, 24 and 36 months